We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.


29 September 2006 By Robert Cyran

The drug group s stock has largely recouped its losses since the drug s recall. In fact, Merck now trades at a premium to rival Pfizer This makes little sense. Merck s earnings growth should be stagnant over the next few years. And Vioxx s legal costs could be staggering.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)